so can be substituted for the reference drug without any prescriber intervention. "While interchangeable use of biosimilars is already practiced in many member states, this joint position ...

Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs.